We compared the prophylactic activities of six fluoroquinolones against Pneumocystis carinii pneumonia in immunosuppressed rats. Pefloxacin was the only agent which was as effective as the reference drug trimethoprim-sulfamethoxazole. Clinical trials with pefloxacin in patients at risk for P. carinii pneumonia appear to be justified.
experiments which included untreated control and TMP-SMX-treated groups in each experiment.
After 4 weeks of prophylaxis and 24 h after the last drug administration, the anesthetized rats were exsanguinated via the abdominal aorta. The lungs were weighed, and one portion was used for quantification of P. carinii cysts and the other for antibiotic assay. P. carinii cysts were quantified by the technique of Walzer et al. (24) . Two 5-,ul drops of the enzymatically digested lungs were placed on a slide, dried, and stained with toluidine blue 0 (9). Cysts were either blindly counted in duplicate in the whole drop or, when too many, calculated by the technique of Yoshida and Ikai (26) . Concentrations of CIP, SPFX, TEM, and PEF in plasma and lungs were measured by high-pressure liquid chromatography (3, 3a) . The lung contamination by the residual blood determined by the technique of Cross et al. (4) was found to be negligible (6.5% of serum). P. carinii cyst counts were analyzed by one-way analysis of variance and Student's t test.
After the 4-week period of immunosuppression, as no differences between untreated control groups and TMP-SMX-treated groups for each experiment were found, the results were combined to facilitate presentation of the data. All the control rats were heavily infected with P. carinii cysts (5.7 x 106 cysts per g). TMP-SMX and PEF were equally effective in preventing PCP, with median counts of 9 x 102 and 2.7 x 103 cysts per g of lung tissue, respectively (Table 1) . TEM CIP, SPFX, and NOR were ineffective (Fig. 1) . The mean concentrations of the quinolones are shown in Table 2 . Pulmonary concentrations of PEF and SPFX were similar and were approximately seven times higher than those of TEM and CIP. Our results show that PEF, when administered orally three times a week at 100 mg/kg for 4 weeks, is as effective as TMP-SMX (40 and 200 mg/kg, respectively, s.c. twice weekly) in preventing PCP in rats. The other fluoroquinolones tested were either poorly effective (TEM and OFL) or ineffective (CIP, SPFX, and NOR). There are few studies of quinolone activity against parasitic and fungal infections: Salmon et al. (22) recently showed that PEF was more effective than CIP against Plasmodium falciparum in mice, although it is ineffective against Toxoplasma gondii (5a).
Twenty-four hours after the last quinolone administration, higher concentrations in plasma and lungs were obtained with SPFX and PEF than with TEM and CIP. The differences could be explained by the longer plasma half-lives of PEF (18) and SPFX (20) (3.3 and 3.8 h, respectively) than of the other quinolones (1 to 2 h) (10, 16, 19, 20) . Higher concentrations in lungs may be obtained with larger doses. A lower level of lung diffusion cannot explain the difference in efficacy between PEF and SPFX, since concentrations in lungs were the same, whereas only PEF was effective in preventing PCP. Although OFL and NOR were not tested, since Azoulay-Dupuis et al. (1) have shown that similar concentrations of OFL and CIP are achieved in the lungs of mice, it seems reasonable to think that similar concentrations in lungs were achieved with CIP and OFL. The primary target of fluoroquinolones is DNA-gyrase (25) . PEF could possibly act on this enzyme system in P. carinii, but this would not explain the discrepancy among the quinolones tested. Kovacs et al. (17) demonstrated that agents clinically effective in PCP (TMP-SMX, pentamidine, and dapsone) inhibit de novo folate synthesis by P. carinii in vitro. Such a mechanism of action has not been described for fluoroquinolones. PEF does not appear to act on this metabolic pathway in P. carinii, since it is ineffective against T. gondii, a pathogen which possesses the same enzyme necessary for de novo folate synthesis (17) .
As has been demonstrated for two sulfonylurea compounds (15), the specific activity of PEF may be due to a particularity of its structure, given the inactivity of NOR, its major metabolite. On the basis of this study, clinical trials of PEF for the prophylaxis of PCP in patients with AIDS and in patients who present adverse reactions to traditional drugs appear to be justified.
